Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF by Weiss, Emmanuel et al.
Frontiers in Immunology | www.frontiersin.
Edited by:
Amiram Ariel,











†These authors share first authorship
‡These authors share senior
authorship
Specialty section:
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology
Received: 19 October 2020
Accepted: 15 December 2020
Published: 05 February 2021
Citation:
Weiss E, de la Grange P, Defaye M,
Lozano JJ, Aguilar F, Hegde P, Jolly A,
Moga L, Sukriti S, Agarwal B, Gurm H,
Tanguy M, Poisson J, Clària J,
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Background and Aims: Patients with cirrhosis and acute-on-chronic liver failure (ACLF)
have immunosuppression, indicated by an increase in circulating immune-deficient
monocytes. The aim of this study was to investigate simultaneously the major blood-
immune cell subsets in these patients.
Material and Methods: Blood taken from 67 patients with decompensated cirrhosis
(including 35 critically ill with ACLF in the intensive care unit), and 12 healthy subjects, was
assigned to either measurements of clinical blood counts and microarray (genomewide)
analysis of RNA expression in whole-blood; microarray (genomewide) analysis of RNA
expression in blood neutrophils; or assessment of neutrophil antimicrobial functions.
Results: Several features were found in patients with ACLF and not in those without
ACLF. Indeed, clinical blood count measurements showed that patients with ACLF were
characterized by leukocytosis, neutrophilia, and lymphopenia. Using the CIBERSORT
method to deconvolute the whole-blood RNA-expression data, revealed that the hallmark
of ACLF was the association of neutrophilia with increased proportions of macrophages
M0-like monocytes and decreased proportions of memory lymphocytes (of B-cell, CD4 T-
cell lineages), CD8 T cells and natural killer cells. Microarray analysis of neutrophil RNA
expression revealed that neutrophils from patients with ACLF had a unique phenotypeorg February 2021 | Volume 11 | Article 6190391
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Frontiers in Immunology | www.frontiersin.including induction of glycolysis and granule genes, and downregulation of cell-migration
and cell-cycle genes. Moreover, neutrophils from these patients had defective production
of the antimicrobial superoxide anion.
Conclusions: Genomic analysis revealed that, among patients with decompensated
cirrhosis, those with ACLF were characterized by dysregulation of blood immune cells,
including increases in neutrophils (that had a unique phenotype) and macrophages M0-
like monocytes, and depletion of several lymphocyte subsets (including memory
lymphocytes). All these lymphocyte alterations, along with defective neutrophil
superoxide anion production, may contribute to immunosuppression in ACLF,
suggesting targets for future therapies.Keywords: myeloid cells, innate lymphoid cells, adaptive immune cells, sepsis, organ failure, immunotherapiesINTRODUCTION
Acute-on-chronic liver failure (ACLF), which develops in patients
with acutely decompensated cirrhosis, is characterized by the
existence of organ failure(s) and high in-hospital mortality (1, 2).
ACLF is associated with systemic inflammation as indicated by
blood leukocytosis (1, 2), and high plasma levels of C-reactive
protein (1, 2) andcytokines andchemokines (3, 4).White blood-cell
count is a component of the chronic liver failure consortiumACLF
scoring system,which accurately predicts earlymortality in patients
with ACLF (5). It has been suggested that, in ACLF, peripheral
leukocytosis is enriched in effector immune cells that have a high
potential to cause tissue damage (2). ACLF is also characterised by
systemic inflammation which is known to be energetically
expensive and may thus skew nutrients otherwise required for
other metabolic processes towards immune cells. This would
therefore deny peripheral organs the required nutrients which
may result in systemic organ failure (6).
There are studies concentrating on peripheral-blood myeloid
mononuclear cells involved in innate immunity (4, 7–11),
showing, for example, that patients with ACLF, whether
critically ill or not, have increased frequency of CD14+
monocytes expressing the receptor tyrosine kinase MerTK
(hereafter called MerTK) (4, 10) and CD14+CD15-HLA-DR-
myeloid-derived suppressor cells (9). Both subsets of myeloid
mononuclear cells have suppressed innate responses to bacterial
pathogen-associated molecular patterns (PAMPs) (4, 9, 10).
These alterations may, therefore, favor the development of
bacterial infections that are frequent complications of ACLF
(12, 13). Another study found decreased frequencies of other
myeloid mononuclear cells (conventional dendritic cells
[DCs] and plasmacytoid DCs) in patients with severe alcoholic
hepatitis, including patients who had ACLF (11). Several studies
have showed alterations in neutrophils (14–16) and lymphocytes
(7, 17–19) in patients with decompensated cirrhosis. However,
until now there has been no comprehensive description of theliver failure; CIBERSORT, cell-type
sets of RNA transcripts; AD, acute
is; HUVEC, human umbilical vein
eucyl-phenylalanine.
org 2landscape of blood immune-cell subsets in patients with ACLF,
in particular critically ill patients admitted to the intensive care
units (ICUs) and who have an especially poor prognosis. A better
knowledge of circulating immune-cell landscape in patients with
ACLF could provide new insights into the pathophysiology of
systemic inflammation and organ failures and identify targets for
therapies, which are unmet medical needs (2). We therefore
aimed to perform a pilot study with the objective of
characterising white blood cell subsets beyond just monocytes
and dendritic cells, in critically ill patients with ACLF, patients
with decompensated cirrhosis but without ACLF and in healthy
subjects (HS).
To address this question, we performed microarray
(genomewide) analysis of RNA expression in whole-blood
from study individuals. Indeed, a large number of information
about a variety of circulating immune-cell subsets have been
identified from genomewide analysis of RNA expression in a
single blood sample obtained in each study individual (20–23).MATERIAL AND METHODS
Patients
The core study was a pilot aiming to investigate clinical complete
blood counts and whole-blood transcriptome in patients with
biopsy-proven cirrhosis admitted to the Hepatology and Liver
Intensive Care Unit at Beaujon Hospital, Clichy, France (Table
S1). The study protocol was approved by the local human
research ethics committee (Supporting Methods). Written
informed consent before enrollment or delayed consent was
obtained from each patient, or legal surrogate. Every patient
with ACLF was admitted to the ICU for organ support; blood
used for whole-blood transcriptomics was taken within 24 h after
admission to the ICU. We used criteria developed by the
European Foundation for the Study of Chronic Liver Failure
for the diagnosis of acutely decompensated cirrhosis, organ
failures, and ACLF grades (Table S2) (1, 5, 24).
Of the 31 patients who were enrolled in the core pilot study,
24 were nonelectively admitted to the hospital [including 17
critically ill patients with ACLF (94% of them having circulatoryFebruary 2021 | Volume 11 | Article 619039
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without ACLF (a group hereafter called AD)], and seven were
admitted for therapeutic paracentesis of refractory ascites [a
group hereafter called advanced cirrhosis (AC)] (Table 1). Of
note, patients with AC were stable; indeed, none of the patients
with AC had ongoing or recently treated (less than 1 week)
bacterial infection or gastrointestinal hemorrhage. During the 90
days following enrollment, the number of patients who received
a liver transplant was 4, 3, and 3, in the ACLF, AD, and AC
groups, respectively. The 90-day transplant-free mortality rate
was 71%, 14%, and 0%, in the ACLF, AD, and AC
groups, respectively.
Methods
Methods which are described in detail in the Supporting
Information, are summarized as follows.
Microarray (Genomewide) Analysis of Whole-Blood
RNA Expression
Blood was collected in Tempus tubes (Thermo Fisher Scientific,
Waltham,MA). RNAwas extractedusing the 5 PRIMEPerfectPure
RNA blood kit (Thermo Fisher Scientific) according to
manufacturer’s instructions. One hundred nanograms of RNA
per sample were then hybridized on Human Transcriptome
Array 2.0 (HTA2.0, Affymetrix, Santa Clara, CA) at the genomic
platform of the Curie Institute (Paris, France). This array was
designed to measure the RNA expression of 67,528 genes.
Analysis and visualization of the Human Transcriptome Array
2.0 dataset were made using EASANA® (GenoSplice technology),
which was based on the GenoSplice’s FAST DB® annotations (18).
Expression data were log2-transformed and used for two purposes.
First, Student’s t-test were used for identification differentially
expressed genes (DEGs). Genes with a fold change >1.5-fold and
P <0.05 were considered as differential expressed. Then, we
performed enrichment analysis using as gene sets, the 346 blood
transcription modules (hereafter referred to as BTMs) that have
been developed by Li, Rouphael, Duraisingham, et al (21). andwere
publicly available (Table S3). These BTMs have been computed
using transcriptomic data obtained in peripheral-blood
mononuclear cells from individuals under various immunological
stimuli (21). Each BTM contained a variable number of co-
expressed genes and has received an identification number. A
large number of BTMs were related to specific immune-cell
subsets; for example, the BTMs “M.37.1: enriched in neutrophils
(I)”; “M11.0: enriched inmonocytes (II); “M7.0: Enriched in T cells
(I)”; “M7.2: enriched in NK cells (I)”; “M47.0: enriched in
B cells (I)”. Other modules were related to immune signaling; for
example, “M16:TLR and inflammatory signaling”;M37.0: immune
activation - generic cluster” (Table S3). Enrichment analysis also
used other publicly available data bases such as Reactome pathways
(https://reactome.org) as gene sets.
Second, the CIBERSORT software package was used for
deconvoluting the blood RNA microarray data (22). R values
were calculated to assess correlations of complete blood counts
inferred from CIBERSORT and counts measured by clinical
laboratories. Inferred CIBERSORT lymphocyte counts were
calculated as the sum of the counts of naive B cells, memory BFrontiers in Immunology | www.frontiersin.org 3cells, CD8 T cells, naive CD4 T cells, resting memory CD4 T
cells, and activated memory CD4 T cells (23). The counts of
monocytes, macrophage M0- and macrophage M2-like
monocytes were summed to infer CIBERSORT monocyte
counts (23).
Microarray (Genomewide) Analysis of RNA
Expression in Blood Neutrophils
RNA was extracted from freshly isolated neutrophils. One
hundred nanograms of RNA per sample were then hybridized
on Clariom S Array, Human (Affymetrix) at the genomic
platform of the Curie Institute (Paris, France). This array was
designed to measure the RNA expression of ~20,800 genes.RESULTS
ACLF Associates Blood Leukocytosis,
Neutrophilia, and Lymphopenia
Clinical complete blood counts obtained on admission in the 31
French patients with cirrhosis showed that ACLF was
characterized by significant increases in white-cell count (i.e.,
leukocytosis), differential and absolute neutrophil counts (i.e.,
neutrophilia), and significant decreases in differential
lymphocyte count (i.e., lymphopenia), as compared with the
two other groups (AC and AD) (Figure 1A, Figure S1). Absolute
lymphocyte count, and monocyte counts (differential and
absolute) did not significantly differ between ACLF and the
two other groups (Figure 1A, Figure S1). No significant
differences in blood counts were seen between AC and AD.
Similar findings (Figures S2A, B) were obtained in an
independent English cohort including 91 patients with AD and
203 critically ill patients with ACLF (Supplementary Methods;
Table S4). In both, the French cohort (Figure 1A) and the
English cohort (Figure S2C), there was a significant negative
correlation between differential neutrophil count and differential
lymphocyte count, indicating a dichotomic regulation of
circulating immune cells, opposing neutrophils to lymphocytes,
and culminating in ACLF.
Validation of the CIBERSORT-Inferred
Blood Counts
We found that the RNA microarray–inferred white-cell counts
(calculated based on the results of the CIBERSORT method;
Table S5) (23) were positively correlated with clinical laboratory
measurements of complete blood counts (Figure 1B), which
suggested that microarray analysis of whole-blood RNA was of
sufficient quality to provide information that correlated with
criterion-standard clinical measurements of blood counts.
RNA Identification of Dysregulated Blood
Immune-Cell Subsets in ACLF
Genomewide analysis of whole-blood RNA expression
(microarrays) was performed in the 31 patients from the
French cohort and 7 HS (healthy subjects) (Table S1).
Unsupervised hierarchical clustering analysis of the resultsFebruary 2021 | Volume 11 | Article 619039



















Median age (IQR) − yr 59 (53–64) 57 (52–59) 58 (53–60.5) 0.81 − −
Male sex – n (%) 7 (100) 3 (42.9) 13 (76.5) 0.06 − −
Etiology or cirrhosis – n (%) 0.45 – –
Alcoholic liver disease 6 (86) 3 (43) 12 (70)
Nonalcoholic
steatohepatitis
1 (14) 2 (28) 3 (18)
Chronic hepatitis C 0 (0) 1 14) 2 (12)
Chronic hepatitis B 0 (0) 1 (14) 0 (0)
Acute precipitants – n (%) − − 0.66
Sepsis 0 (0) 2 (28.6) 8 (47.1)
Excessive alcohol consumption 0 (0) 2 (28.6) 1 (5.9)
Hemorrhage 0 (0) 1 (14.3) 4 (23.5)
Other 0 (0) 1 (14.3) 2 (11.8)




– 55 (52–59) – – – –
Median MELD score (IQR) 10 (8–18) 21 (15–25) 35 (26–39) <0.001 0.05 0 .003
Median CLIF-C Organ Failure score (IQR) – 8 (7–9) 14 (12–15) – – <0.001
Median CLIF-C ACLF
score (IQR)
– – 67 (59–69.5) – – –
Individual organ system failuresa – n (%)
Kidney 0 (0) 0 (0) 11 (64.7) <0.001 1 0.005
Lungs 0 (0) 0 (0) 10 (59.0) 0.003 1 0.02
Liver 0 (0) 1 (14.3) 4 (23.5) 0.37 − −
Coagulation 0 (0) 1 (14.3) 11 (64.7) 0.005 0.71 0.05
Brain 0 (0) 0 (0) 3 (17.6) 0.26 − −
Circulation 0 (0) 0 (0) 16 (94.0) <0.001 1 <0.001
ACLF Gradea – n (%) – – –
Grade 1 0 (0) 0 (0) 1 (5.9)
Grade 2 0 (0) 0 (0) 2 (11.8)
Grade 3 0 (0) 0 (0) 14 (82.4)






Median absolute count (IQR) − per mm3
Neutrophils 4,250 (2595–
4940)











1,000 (925–1,535) 1,080 (700–
1,600)
0.95 – –
Median differential countc (IQR) − %
Neutrophils 66 (46–72) 60 (56–66) 81 (70–90) <0.001 0.53 <0.001
Lymphocytes 18 (15–3) 18 (13–27) 11 (4–16) 0.008 0.9 0.016
Monocytes 12 (8–13) 13 (7–22) 9 (4–13) .14 − −
Median hemoglobin (IQR) − g/dl 11.6 (10.1–
14.1)
7.8 (7.1–10.1) 8.8 (8.1–11.3) 0.02 0.02 0.166









Median International Normalized Ratio (IQR) 1.42 (1.20–
1.86)
1.64 (1.54–2.23) 2.80 (2.10–3.10) <0.001 0.13 0.013
Median serum sodium (IQR) − mmol/L 135 (133–
138)
133 (131–135) 133 (125–137) 0.45 − −
Median serum creatinine (IQR) − mg/dl 0.74 (0.68–
0.85)
0.73 (0.56–1.51) 2.40 (1.90–3.10) 0.001 0.46 <0.001
Median C-reactive protein (IQR) − mmol/L 7 (7–10) 11 (7–24) 44 (21–94) 0.36 − −
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different between patients with ACLF and all the other study
persons (Figure S3). Microarray results were validated by using
RT-qPCR in a random set of genes (Figure S4).
Then, the results of microarray analysis were used to establish
the lists of DEGs, corresponding to 3 pairwise comparisons: AC
versus HS, AD versus HS, and ACLF versus HS (hereafter
referred to as AC/HS, AD/HS, and ACLF/HS, respectively;
Table S6), that were visualized using volcano plots (Figure
2A). In AC/HS (Figure 2A, left), the 5 top upregulated genes
included SCLC38A5, CTSE, AHSP, NRG1, LINC00278 while the
5 top downregulated genes included PPBP,MAP3K7CL, MS4A1,
RAB27B, SDPR. In AD/HS (Figure 2A, middle), the top
upregulated genes included AHSP, RSAD2, IFI27, IFI44L,
THEM5 while the top downregulated genes included
MAP3K7CL, KLRC4, JCHAIN, MS4A1, LRNN3. In ACLF/HS
(Figure 2A, right), the top upregulated genes included CD177,
MCEMP1, ARG1, MMP9, PFKFB2 while the top downregulated
genes included CD3G, KLRC4, GNLY, FGFBP2, GPR174. Of
note, in ACLF/AC the 5 top upregulated genes (Figure S5; Table
S6) were similar to the corresponding top upregulated genes in
ACLF/HS (Figure 2A, right). In ACLF/AC, the only top
downregulated gene shared with ACLF/HS was CD3G. In
ACLF/AC, the other top downregulated genes were FCER1A,
CCR3, CLC, CX3CR1 (Figure S5; Table S6).
In addition, we used Venn diagrams to visualize the number
of DEGs unique to each comparison. There were few DEGs
unique to AC/HS or AD/HS (120 and 147, respectively) while
there were 1497 DEGs unique to ACLF/HS, indicating changes
in blood transcriptome that were specific for ACLF (Figure 2B).
ACLF Associates With Increased Innate
Inflammatory Signatures in Blood
To gain insights into the dynamics of transcription at the single-
gene level across the study groups, we first used the comparison
of ACLF versus HS to rank fold-changes in gene expression,
from the highest to the lowest fold-change value, and thenFrontiers in Immunology | www.frontiersin.org 5aligned, for each gene, its fold-change values in the two other
pairwise comparisons (AC/HS, AD/HS; Table S6). Using the
fold-changes values for the 50 most upregulated genes in ACLF/
HS, and the corresponding values in the two other comparisons
(Table S6), we drew a Cleveland plot showing fold-changes for
each gene across the three pairwise comparisons (Figure 2C,
top). For each gene, the fold-change was higher in ACLF/HS
than the fold-change in the two other comparisons, and, in both
AC/HS and AD/HS, very few genes passed the filter defining
significant upregulation (Figure 2C, top; Table S6). We also
noted that 22 of the 50 most upregulated genes in ACLF/HS were
related to innate immunity; for example CD177 [that had the
highest expression (Figures 2A, C)], MMP8, MMP9, ARG1,
S100A12, were neutrophil genes. Together, these findings
suggested that upregulated genes in ACLF/HS composed a
distinctive gene signature of ACLF. Then, the BTM gene
modules (Table S3) (21) and canonical pathways (in
particular, Reactome pathways) were used as gene sets to
perform enrichment analysis of the three complete lists of
upregulated genes (ACLF/HS, AD/HS, AC/HS; Tables S7A, C,
E, G, I, K). The 483 genes upregulated in ACLF/HS were
significantly enriched in genes involved in innate immunity,
including neutrophil, monocyte, Toll-like receptor and
inflammatory signaling genes (Figure 2D, left) (Table S7A). In
addition, analysis of Reactome pathways identified enrichment
in neutrophil granule genes (Table S7C). Importantly, the lists of
upregulated genes in the two other comparisons (AD/HS, AC/
HS) had a totally different enrichment profile (Figure 2D, left;
Tables S7E, G, I, K), indicating the specificity of the innate
inflammatory gene signature in blood from patients with ACLF.
To capture the dynamics of upregulation of co-expressed
genes across study groups, we computed gene clusters using
whole-blood transcriptomic data, with the transcriptome in HS
as a reference (Supplementary Methods). Each cluster was
composed of significantly correlated expression values across
the three patients’ groups; a gene included in a given cluster was



















Median aspartate aminotransferase (IQR) −
U/L
58 (33–72) 50 (46–90) 104 (61–234) 0.05 − −
Median alanine aminotransferase (IQR) − U/
L
26 (12–33) 28 (14–37) 40 (20–83) 0.12 − −
Median total bilirubin (IQR) − mg/dl 2.47 (0.80–
4.71)




Death without transplantation by 90 days –
n (%)
0 (0) 0 (0) 12 (71) – – –
Liver transplantation – n (%) 3 (43) 3 (43) 4 (23.5) – – –February 2021 | VolumeP values were obtained using Kruskal–Wallis test and Mann–Whitney test and the chi-square test or Fisher’s exact test, as appropriate. ACLF denotes acute-on-chronic liver failure; IQR,
interquartile range; CLIF-C, Chronic Liver Failure-Consortium; and MELD, Model for End Stage Liver Disease.
aDefined in Table S2.
bNormal range for blood white-cell count is 4,500–11,000 per mm3.
cNormal ranges for differential counts are 40%–70% for neutrophils, 4%–11% for monocytes, and 22%–44% for lymphocytes.11 | Article 619039
Weiss et al. Circulating Immune Cells in ACLFgene clusters (Figure S6A, Table S8A), which were numbered
arbitrarily by the algorithm, and included a total of 2116 genes.
For each cluster, we computed an eigengene (21) which is a gene
summarizing the global behavior of the cluster member genes
(Figures S6A, B). Cluster 2 was interesting because it was the
second largest cluster (416 genes) and 70% of the cluster member
genes were upregulated in ACLF/HS. Cluster 2 eigengene was
upregulated in ACLF versus the other patients’ groups and did
not differ between AC and AD, indicating that cluster 2 capturedFrontiers in Immunology | www.frontiersin.org 6gene upregulation that was specific for ACLF (Figure S6B).
Finally, the profile of enrichment of cluster 2 (Figure S6C, Table
S8) was very similar to that of upregulated genes in ACLF/HS, in
particular member genes were enriched in innate inflammatory
genes. Together these findings confirmed that the orchestrated
activation of the blood innate inflammatory signature was a
molecular hallmark of ACLF.
One additional mean of deconvoluting the RNA microarray
data, the CIBERSORT software package (22), showed that thereA
B
FIGURE 1 | Results of clinical blood counts and RNA microarray-inferred blood counts. (A) Clinical complete blood counts in three groups of patients with cirrhosis:
AC (orange circles, n=7), AD (red square, n=7) and ACLF (purple triangle, n=17). P values were obtained using Kruskal–Wallis test and Mann–Whitney test.
**P <0.01; *P <0.05. (B) Neutrophil, lymphocyte, and monocyte counts in paired clinical complete blood counts as compared with the CIBERSORT-inferred blood
counts from RNA microarray data obtained with the use of peripheral blood (31 paired specimens). The shaded areas represent the 95% confidence intervals. AC
denotes advanced cirrhosis, AD acute decompensation, and ACLF acute on chronic liver failure.February 2021 | Volume 11 | Article 619039
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B
D
FIGURE 2 | Distinctive transcriptional characteristics of ACLF. (A) Volcano plots of differential gene expression between each patients’ group [AC (n=7); AD (n=7);
ACLF (n=17)] relative to healthy subjects [HS (n=7)], with significance (−log10 P value) plotted against the log2 fold-change (patients:HS ratio). Genes were considered
as differentially expressed when P was <0.05 (or −log10 P >1.3; dashed horizontal line) and fold-change >1.5 [or log2 fold-change >0.58 for upregulation or log2 fold-
change <-0.58 for downregulation (right and left dashed vertical lines, respectively)]. Gray points indicate genes with no significant difference in expression, salmon
indicates genes with significantly increased expression in patients and blue indicates genes with significantly decreased expression in patients. Representative
differentially expressed genes are shown. CD177 was the most upregulated gene in ACLF versus HS. Between-group comparisons were performed using Student’s
t-test. (B) Venn diagram showing the number of up- and downregulated genes that were unique or not to each of the three pairwise comparisons. (C) Cleveland plot
showing the fold-changes for the 50 most upregulated genes in ACLF versus HS (top) and in the 50 most downregulated in this comparison (bottom). The dashed
horizontal line separates upregulated genes from down regulated genes. For each gene, the fold-change of expression is also shown for two other pairwise
comparisons: AD versus HS and AC versus HS. A dashed vertical line (right) indicates the threshold of 1.5 fold-change versus HS and the other dashed vertical line
(left) indicates the threshold of -1.5 fold-change versus HS. (D) Results of enrichment analysis of predefined data sets (which, unless specified, were blood
transcription modules (21)) with upregulated genes (left) and downregulated genes (right), both in ACLF versus HS. The enrichment of these gene sets with genes
that were upregulated (left) or downregulated (right), in AC versus HS and AD versus HS genes, are also shown.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6190397
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between AC and AD, and that these two groups had modest
changes restricted to the blood monocyte/macrophage
compartment relative to HS (Figure 3). In contrast, blood in
ACLF had significant increases in the proportions of neutrophils
(relative to AC) and macrophage M0-like monocytes (relative to
HS and AC) (Figure 3). Using flux cytometry in additional
individuals, we found that ACLF was associated with a
significant increase in the frequency of a monocyte subset
(Figure S7). Together these findings indicate that, in blood
from patients with ACLF, the development of an innate
inflammatory gene signature coincided with increases in
certain myeloid cell populations (neutrophils and macrophage
M0-like monocytes) that were unique to these patients.
ACLF Associates With Depletion of Several Blood
Lymphocyte Subsets
Using the fold-changes values for the 50 most downregulated
genes in ACLF/HS, and the corresponding values in the two
other comparisons (Table S6), we drew a Cleveland plot showing
fold-changes for each gene across the three pairwise comparisons
(Figure 2C, bottom). For each gene, the fold-change was greater
in ACLF/HS than the fold-change in the two other comparisons.
However, in both AC/HS and AD/HS, several genes fulfilled the
criteria defining downregulation (Figure 2C, bottom; Table S6),
suggesting a progressive decrease in the expression of these genes
from AC or AD to ACLF. For example, TCF7 and LEF1, that are
crucial for establishment of central memory CD8 T cells, were
downregulated, respectively, by 1.6-, 1.6-, 2.7-fold and by 1.6-,
1.8-, 4.3-fold, in AC/HS, AD/HS, and ACLF/HS (Table S6).
Then, we performed BTM-based analyses and found that the
1,086 downregulated genes in ACLF/HS were significantly
enriched in T-cell and NK-cell genes (Figure 2D, right; Table
S7B). Moreover, Reactome pathways analysis showed that
downregulated genes in this comparison were significantly
enriched in genes related to RNA metabolism and translation
of RNA into proteins (Table S7D), indicating a decrease in the
constitutive apparatus required for gene induction and
expression, consistent with an increased threshold for
lymphocyte activation. Importantly, the lists of downregulated
genes in the two other pairwise comparisons (AC/HS, AD/HS)
were also significantly enriched in T-cell, and NK-cell genes
(Figure 2D, right; Tables S7F, J), and genes related to RNA
metabolism and translation (Tables S7H, L) confirming that
lymphocyte gene downregulation was not unique to ACLF. Of
note, our “home-made” analysis revealed that the eigengene
representative of the largest gene cluster (cluster 3, 995 genes)
progressively decreased from HS to ACLF; the decrease was
already significant in AC relative to HS and reached its
maximum with ACLF (Figure S6B). Ninety-two percent of
cluster 3 member genes were downregulated in ACLF/HS.
Moreover, the profile of enrichment of cluster 3 (Table S8)
was very similar to that of downregulated genes in ACLF/HS, in
particular member genes were enriched in genes related to T
cells, B cells, and NK cells. Together these findings confirmed
that decompensated cirrhosis was characterized by a progressiveFrontiers in Immunology | www.frontiersin.org 8decline in the expression of genes related to lymphocytes, the
lowest gene expression being observed in ACLF.
The use of the CIBERSORT method showed that ACLF was
associated with significant decreases in several lymphocyte
populations including memory B cells; resting memory CD4 T
cells; CD8 T cells; and NK cells (Figure 3). The ACLF-associated
depletion was restricted to these cells because the proportions of
plasma cells; naïve CD4 T cells; activated memory CD4 T cells;
and regulatory CD4 T cells (Tregs) were not affected in ACLF
(Figure 3). Of note, there were no significant alterations in
lymphocyte proportions in AC and AD (Figure 3). Together,
these results indicated that the depletion of certain blood
lymphocyte subsets was unique to ACLF, and contributed to
both the decrease in clinical differential lymphocyte counts
(Figure 1A) and the maximum reduction in lymphocyte-
related genes (Figure 2D), observed in this syndrome. In
addition, the ACLF-associated lymphocyte depletion measured
with the CIBERSORT method was consistent with results of our
analysis of the blood lymphocyte compartment using flux
cytometry in additional individuals (Figure S8). In addition,
flux cytometry identified a significant decrease in NK T cells
(which are innate-like killer T cells; Figure S8).
Unique Phenotype of Circulating
Neutrophils in ACLF
Blood Neutrophils Are Activated in ACLF
Because increased blood neutrophil population was a major
feature of ACLF (Figure 1A), we performed genomewide
analysis of RNA expression in freshly isolated peripheral-blood
neutrophils from 15 additional individuals (five HS, five patients
with AC, and five patients with ACLF; Tables S1 and S9). There
were only 140 DEGs (71 upregulated) in AC/HS and 832 DEGs
(420 upregulated) in ACLF/HS (Figure 4A; Table S10A). Next,
we focused on the list of DEGs in ACLF/HS, and pathway
analysis of upregulated genes identified that 48 of these genes
were neutrophil granule genes (Figure 4B; Table S10B), findings
consistent with analysis of upregulated genes in whole-blood
(Figure 2D). Granule genes encode proteins which are expressed
in the lumen or membrane of different types of neutrophil
granules under steady-state, and are released via exocytosis,
following neutrophil activation (25). CD177, which was the
second most upregulated gene in ACLF/HS (Figure 4A), was
in the list of 48 upregulated granule genes. The CD177 protein
resides in the granule membrane under basal conditions, and is
mobilized to the cell surface following neutrophil activation (25,
26). Using flow cytometry, we investigated CD177 protein
expression in neutrophils obtained from two additional series
of individuals, one enrolled in France (seven HS, five patients
with AC, and seven with ACLF, Table S1) and the other in India
(eight patients with AC and 12 with ACLF; Tables S1 and S11).
The results obtained in both series showed that patients with
ACLF had increases in the absolute number and frequency of
CD177+ neutrophils (Figure 4C and Figure S9, for French and
Indian patients, respectively). Moreover, mean fluorescence
intensity was significantly increased in neutrophils from
French patients with ACLF (Figure S10), confirming increasedFebruary 2021 | Volume 11 | Article 619039
Weiss et al. Circulating Immune Cells in ACLFCD177 expression in these cells. Of note, upregulated genes in
ACLF/HS were significantly enriched in genes related to
carbohydrate metabolism (Figure 4B), consistent with
metabolic reprogramming in activated neutrophils (27).
Collectively, our analysis of upregulated genes in ACLF/HS
indicated that circulating neutrophils were activated in ACLF.Frontiers in Immunology | www.frontiersin.org 9In addition, pathway analysis of downregulated genes in ACLF/
HS revealed that these genes were related to TP53-induced
transcription (involved in cell death), activation of formins
(involved in cytokinesis), cell cycle, and mitosis (both involved
in proliferation) (Figure 4B; Table S10C), which are other
features of unique neutrophil phenotype in ACLF (28).FIGURE 3 | The CIBERSORT method identifies alterations in blood immune-cell subset composition in ACLF. There were seven healthy subjects (HS), seven
patients with advanced cirrhosis (AC), seven patients with acutely decompensated cirrhosis (AD), and 17 patients with ACLF. P values were obtained using one-way
ANOVA and unpaired t-tests.February 2021 | Volume 11 | Article 619039




FIGURE 4 | Unique phenotype of neutrophils from patients with ACLF. (A) Volcano plots of differential neutrophil gene expression between AC and HS and ACLF
versus HS. There were five healthy subjects (HS), five patients with advanced cirrhosis (AC), and five patients with ACLF. Between-group comparisons were
performed using unpaired Student’s t-test. CD177 was the most upregulated gene in ACLF versus HS. (B) Enrichment of Reactome data sets with differentially
expressed genes between ACLF and HS. (C) Absolute number and frequency of CD177+ neutrophils in blood from HS (green diamonds, n=7), patients with AC
(orange circles, n=5) and patients with ACLF (purple triangles, n=7). (D) Increased adhesion to HUVECs of neutrophils from ACLF patients relative to neutrophils from
HS. Neutrophils from HS (n=7) and patients (n=7) were freshly isolated; their adherence to HUVECs was measured using flow cytometry as the ratio of CD66b+
neutrophil per HUVEC. (E) Defective superoxide production in neutrophils from patients with ACLF is restored by a TLR7/8 agonist. Freshly isolated neutrophils from
13 patients with ACLF and 13 patients with AC were stimulated with fMLP (1 µM) and respiratory burst was monitored using the cytochrome c reduction assay. In
seven patients, neutrophils were pre-treated with the TLR7/8 agonist CL097 (2 µg/ml) for 10 min before stimulation with fMLP. During the same period, median [IQR]
superoxide production in neutrophils from healthy subjects was 19.6 [15.4–27.25]. ***P <0.001; *P <0.05. HUVEC denotes human umbilical vein endothelial cell, and
fMLP N-Formylmethionyl-leucyl-phenylalanine.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 61903910
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Increased Adhesion to Endothelial Cells
Expression of the CD177 protein at the neutrophil plasma
membrane is known to result in neutrophil arrest at the
endothelium surface (26). Because of the elevated frequency of
CD177+ cells among neutrophils from patients with ACLF, we
hypothesized that these neutrophils would exhibit enhanced
adhesion to endothelial cells as compared with neutrophils
from HS. We freshly isolated neutrophils from patients with
ACLF and HS and compared, in vitro, their adhesion to human
umbilical vein epithelial cells (HUVECs) (29). Patients’
neutrophils had an enhanced adherence to HUVECs (Figure
4D). Whether this effect directly or indirectly dependent on
CD177 overexpression should be further investigated.
In ACLF, Blood Neutrophils Have Defect in
Superoxide Anion Production That Is
Pharmacologically Reversible
Neutrophils are the first-line defense against bacterial infections
(30). When stimulated by bacterial cues, such as N-
Formylmethionyl-leucyl-phenylalanine (fMLP), neutrophil
NADPH oxidase is activated to produce large amount of the
antimicrobial superoxide anion (respiratory burst) (30). In its
active form, NADPH is a multiprotein complex comprising
NOX2 which catalyzes superoxide anion production (30). We
(15, 16), and others (14), have shown that compared with
neutrophils form HS, neutrophils from patients with AC have a
defective of superoxide anion production in response to fMLP. This
defect is explained, at least in part, by a degradation of the protein
NOX2 involving the granule protein elastase that has been released
via degranulation (15). Because, as mentioned earlier, there was
evidence of marked neutrophil degranulation in ACLF, we
wondered whether superoxide anion production was affected in
neutrophils from patients with ACLF. To address this question,
neutrophils from two groups of patients (ACLF and AC) were
isolated to investigate the production of superoxide anion in
response to the bacterial fMLP (Supplementary Methods, Table
S1). FMLP-induced superoxide anion production by neutrophils
was significantly lower inpatientswithACLF than in thosewithAC
(Figure 4E), suggesting that ACLF was associated with a major
defect in NADPH oxidase activation.
We have previously shown that neutrophils isolated from
patients with cirrhosis and exposed to CL097 or R848 (which are
agonists for endosomal TLR7/8) had an increased superoxide
production in response to fMLP (15). We investigated the effects
ofCL097on the response to fMLP inneutrophils frompatientswith
ACLF and found that CL097 enhanced fMLP-induced superoxide
production in these cells (Figure 4E). These findings suggest that
the mechanisms resulting in defective superoxide production in
fMLP-stimulated neutrophils from patients with ACLF were
reversible with endosomal TLR7/8 engagement.
DISCUSSION
This pilot study is the first to investigate the landscape of
circulating immune cells in critically ill patients with ACLFFrontiers in Immunology | www.frontiersin.org 11seen during the first 24 h of their ICU stay. We used results of
clinical complete blood count measurements and microarray
(genomewide) analysis of blood RNA expression, in HS and 3
groups of patients with cirrhosis, comprising AC, AD, and
ACLF. In addition to traditional bioinformatic analysis of
transcriptomic data, deconvolution of these data was
performed using the CIBERSORT method, enabling to
enumerate the proportions of immune-cell subsets present in a
given tissue, here the blood (22). The key results were that
patients with ACLF had dysregulation of certain circulating
immune cells, including leukocytosis fueled by increased
populations of neutrophils (that had unique phenotype) and
macrophages M0-like monocytes, and, as expected (31, 32),
decreases in lymphocyte count related to a depletion in
memory lymphocytes (of the B-cell, CD4 T-cell lineages), CD8
T cells and NK cells. Flux cytometry also identified that ACLF
was associated with a decrease in circulating NK T cell
population. The dysregulation of blood immune cells was
unique to ACLF because it was not observed in AC and AD.
One cannot exclude that increases in blood neutrophil
population associated with ACLF was partly due to the
mobilization of a marginated pool of neutrophils (26).
However, a more likely explanation for neutrophilia is the
stimulation of a hematopoietic response program called
emergency granulopoiesis (28, 33). Under acute inflammatory
stresses, such as sepsis, PAMPs, cytokines (granulocyte colony-
stimulating factor [G-CSF], IL-1, TNF-a), or both, stimulate
large-scale de novo production of neutrophils from myeloid
precursors in the bone marrow (33). Patients with ACLF have
increased systemic levels of stimuli for emergency
granulopoiesis, including PAMPs (lipopolysaccharide) (2) and
cytokines, including G-CSF, IL-1, TNF-a (2–4) (Table S12).
In this study, microarray analysis of blood neutrophil RNA
expression enabled us to show that neutrophils from patients with
ACLF overexpressed genes encoding granule proteins (Table S9),
including CD177, which was among the most upregulated
transcript in these cells. Flow cytometry revealed that the
frequency of CD177 was higher in neutrophils from patients with
ACLF.CD177degranulationat the neutrophil plasmamembrane is
a signal for neutrophil arrest at the endothelium surface in tissue
vessels (26).Thus, using ex vivo experiments of neutrophil adhesion
to HUVECs, we found that neutrophils from patients with ACLF
weremore adherent to endothelial cells than their counterpart from
HS. The interaction of activated neutrophils with endothelial cells
may cause endothelium injury and activate local prothrombotic
mechanisms (34). Consistent with this hypothesis, patients with
ACLF had elevated plasma levels of markers for endothelial
dysfunction (Table S12). Therefore, an increased frequency of
CD177+ neutrophils in ACLF might play a major role in the
development of organ failures in this syndrome. This could also
be the case in patients without cirrhosis who have septic shock
because previous studies have shown that CD177 was most
upregulated gene and protein in neutrophils from these
patients (35).
The ACLF-associated depletion in circulating lymphocytes
can have different explanations which are not mutually exclusive.February 2021 | Volume 11 | Article 619039
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sepsis, patients with ACLF may have excessive blood lymphocyte
death (36). Second, one cannot exclude another that, like in other
severe acute inflammatory diseases (37), ACLF was associated with
an increased egress of lymphocytes, from blood to lymphoid or
non-lymphoid tissues, that would contribute to circulating
lymphopenia. Of note, however, in patients without cirrhosis who
had protracted sepsis, blood lymphopenia was associated with
extensive loss of lymphocytes in spleens, intestines, and other
organs (38). Future studies are needed to elucidate the
mechanisms of blood lymphopenia in blood from patients
with ACLF.
Patients with ACLF have immunosuppression which is
indicated by the high incidence of new or secondary bacterial of
fungal infections in these patients (12, 13). Mechanisms driving
immunosuppression in ACLF may include increased numbers of
MerTK-expressingmonocytes (4), andmyeloid-derived suppressor
cells (9), and exhausted T cells (39). Moreover, our study suggests
additionalmechanisms for immunosuppression inACLF, related to
alterations in both neutrophils and the lymphoid lineage. Indeed,
although neutrophils from patients with ACLF had features of
activation, these cells were defective in fMLP-induced neutrophil
production of the antimicrobial superoxide anion (Figure 4E). This
defect, therefore, was a factor of ACLF-associated systemic
immunosuppression. Using the CIBERSORT method, we also
found that ACLF was associated with a systemic depletion of
resting memory CD4 T cells which may play a role in systemic
immunosuppression in this syndrome; thus, memory CD4 T cells
are essential for an immediate response against bacterial infections
(40). Moreover, CD8 T cells, which are involved in elimination of
infected cells (41), hadadecreasedproportion inACLF. Inaddition,
the populationsofNKcells andNKTcells, whichplay an important
role in the innate immune response against microbes (including
fungi) (42) were significantly decreased in blood frompatients with
ACLF. Of note, the CIBERSORT method did not provide explicit
information on CD8 T cells states such as exhaustion andmemory.
Because increased exhausted CD8T cells and decreased inmemory
CD8 T cells are important contributors for immunosuppression
(34, 43), we established a list of genes that are markers for each of
these states (Table S13). In our patients withACLF, we did not find
evidence of an induction of exhaustion markers (such as negative
checkpoint regulators), but identified a downregulation of the gene
signature ofmemory CD8T cells, suggesting that these cellsmay be
involved in immunosuppression associated with ACLF.
A decreased number of memory CD8 T cells are involved in
immunosuppression associated with cancer (43) or sepsis (36). In
the context of cancer, generating more memory CD8 T cells (for
example, through IL-7 or IL-15 pathways) may improve the
outcomes (43). Similar approaches are considered as being of
potential interest for treating immunosuppression in patients with
sepsis (36). Our finding, in ACLF, of downregulation of the gene
signature of memory CD8 T cells may suggests that
immunotherapies with IL-7 or IL-15 might be of interest against
immunosuppression associated with this syndrome. Of note, the
blood expression of IL2RG, encoding the g-chain receptor which is
shared by IL-7 and IL-15 and is indispensable for signaling of theseFrontiers in Immunology | www.frontiersin.org 12cytokines in target cells, was not affected in ACLF (Table S6).
Finally, our result, that a TLR7/8 agonist stimulated production of
superoxide anion in neutrophil from patients with ACLF, requires
confirmation because it suggests another approach against
immunosuppression associated with ACLF.
Our study has limitations, in particular because of the small
number of patients investigated. However, our study enabled to
validate deconvolution of RNA microarray data as a means to
enumerate immune-cell subsets in the blood of patients with
cirrhosis. This approach may therefore be used in large
longitudinal studies assessing, for example, the impact of
therapies on systemic inflammatory cells in patients with
ACLF. It is also important to note that, although a co-
orchestrated decrease in a large number of lymphocyte genes
were significantly downregulated in AD and AC relative to HS
(Figure 2D; Figure S5), the CIBERSORT-inferred proportions
of lymphocyte subsets did not significantly differ in AD/HS and
AC/HS (Figure 3). These findings, therefore, were in sharp
contrast with those obtained in ACLF/HS where maximum
lymphocyte gene downregulation (Figure 2D) coincided with
decreases in certain blood lymphocyte populations (Figure 3).
Collectively, our results suggested a model, in which blood
lymphocyte gene downregulation was a characteristic of
decompensated cirrhosis that preceded the decrease in the
frequency of certain circulating lymphocytes; this decreased
frequency being the hallmark of ACLF.
In conclusion, this pilot study showed that patients with
ACLF had dysregulation in systemic immune cells including
leukocytosis fueled by neutrophils and a monocyte/macrophage
subset, and decreases in lymphocyte count related to a depletion
in memory lymphocytes, CD8 T cells, and NK cells. All these
lymphocyte alterations, along with blood enrichment in
neutrophils defective in superoxide anion production, may
contribute to immunosuppression in ACLF. Finally, our study
suggests the existence of targets for novel therapeutic approaches
for decreasing the risk of infection among patients with ACLF.DATA AVAILABILITY STATEMENT
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